First Quarter Revenue Grows 50% to $52.8 Million; Net Income Increases 66% to $2.1 Million with Adjusted EBITDA Up 71% to $4.9 Million; Cash Position Grows to $24.4 Million
In the news release, PEET'S COFFEE LAUNCHES NATIONWIDE SEARCH FOR ITS FIRST-EVER "CHIEF PLAYLIST OFFICER" TO BEAT AMERICA'S 3PM SLUMP, issued 03-Jun-2026 by PEET'S...
AG1 Pro's advanced formula builds on AG1's clinically-backed formula to include additional research-backed key ingredients, including creatine, that target muscle strength, metabolic resilience, and...
MONTRÉAL, June 08, 2026 (GLOBE NEWSWIRE) -- On June 4, 2026, Saputo Inc. (TSX: SAP) (we, Saputo or the Company) issued its 2026 Saputo Promise Report, which highlights progress in key Environmental, Social, and Governance (ESG) priorities that support operational resilience, disciplined long-term growth, and sustainable value creation.
Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...
Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass...
AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...
Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...
Exotic Pets Steal the Spotlight with Debut Reptilia Carnival and Live Insect Exhibition Featuring Over 50 SpeciesHONG KONG, June 5, 2026 /PRNewswire/ -- Organized...